<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03861234</url>
  </required_header>
  <id_info>
    <org_study_id>1336-0007</org_study_id>
    <secondary_id>2017-001221-40</secondary_id>
    <nct_id>NCT03861234</nct_id>
  </id_info>
  <brief_title>A Study to Test Different Doses of BI 836880 in Patients With an Eye Disease Called Wet Age-related Macular Degeneration (wAMD)</brief_title>
  <official_title>Safety, Tolerability and Pharmacodynamics of Single Rising Intravitreal and Multiple Rising Intravitreal Doses of BI 836880 in Patients With wAMD (Open Label, Non-randomized, Uncontrolled).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study in people with an eye disease called wet age-related macular degeneration&#xD;
      (wAMD). The purpose of the study is to find out how well different doses of a medicine called&#xD;
      BI 836880 are tolerated.&#xD;
&#xD;
      People can participate if they are at least 55 years old and if they have new blood vessels&#xD;
      in their eyes despite treatment (anti-VEGF therapies). The study has 2 parts. In the first&#xD;
      part, people get only 1 dose of BI 836880. This part takes 6 weeks. In the second part,&#xD;
      people get 3 times the same dose of BI 836880. This part takes 6 months. BI 836880 is&#xD;
      injected into the eye. During the entire study doctors regularly check the health of the&#xD;
      participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 27, 2019</start_date>
  <completion_date type="Anticipated">August 8, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 8, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Single Rising Dose (SRD) part: Number of patients with ocular dose limiting events (DLEs) from drug administration till end of trial (EOT)</measure>
    <time_frame>Up to 43 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple Rising Dose (MRD) part: Number of patients with drug related Adverse Events (AEs) from drug administration till end of trial (EOT)</measure>
    <time_frame>Up to 169 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Single Rising Dose (SRD) part: Number of patients with drug related Adverse Events (AEs)</measure>
    <time_frame>Up to 43 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single Rising Dose (SRD) part: Number of patients with any ocular Adverse Events (AEs) in the study eye</measure>
    <time_frame>Up to 43 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Rising Dose (MRD) part: Percent change from baseline in Central Subfield Thickness (CSFT) in the study eye at week 12, for each dose</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Rising Dose (MRD) part: Change from baseline in Best Corrected Visual Acuity (BCVA) in the study eye at week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Rising Dose (MRD) part: Time to recurrence after the last treatment</measure>
    <time_frame>Up to 169 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Rising Dose (MRD) part: Number of patients with any ocular AEs in the study eye</measure>
    <time_frame>Up to 169 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Wet Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>BI 836880</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Rising Dose part followed by a Multiple Rising Dose part</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 836880</intervention_name>
    <description>Solution for Intravitreal (IVT) injection</description>
    <arm_group_label>BI 836880</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women over the age of 55 with active Choroidal Neovascularisation (CNV)&#xD;
             secondary to Age-related macular degeneration (AMD) despite anti-Vascular Endothelial&#xD;
             Growth Factor (VEGF) therapies (at least 3 prior injections with the last injection&#xD;
             within 12 to 4 weeks before treatment). Active CNV secondary to AMD is to be defined&#xD;
             either by recent fluorescein or Optical coherence tomography (OCT) angiogram within 4&#xD;
             weeks prior to screening or fluorescein or OCT angiogram obtained prior to first anti&#xD;
             VEGF-treatment to confirm the diagnosis and still active according to investigator&#xD;
             judgement.&#xD;
&#xD;
          -  For MRD part only: Central subfield retinal thickness &gt;350 microns in the study eye on&#xD;
             Heidelberg Spectralis Spectral Domain Optical Coherence Tomography (SD-OCT)&#xD;
&#xD;
          -  Presence of sub- and/or intraretinal fluid on SD-OCT in the study eye&#xD;
&#xD;
          -  Any active CNV with subfoveal leakage in the study eye as determined by OCT&#xD;
&#xD;
          -  No subretinal hemorrhage involving the fovea in the study eye No significant subfoveal&#xD;
             fibrosis or atrophy on SD-OCT in the study eye that, in the opinion of the&#xD;
             investigator, is able to prevent improvement in Best Corrected Visual Acuity (BCVA)&#xD;
             and/or Central Subfield Thickness (CSFT)&#xD;
&#xD;
          -  Best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity (VA)&#xD;
             in the study eye between 70 and 24 letters inclusive (approximately 20/40 and 20/320&#xD;
             or 6/12 and 6/95) at screening.&#xD;
&#xD;
          -  Best-corrected VA in the non-study eye better than best-corrected VA in the study-eye.&#xD;
             If both eyes are eligible and have identical VA the investigator may select the study&#xD;
             eye.&#xD;
&#xD;
          -  Male or female patients. Women of childbearing potential (WOCBP)1 cannot be included.&#xD;
             Men able to father a child must be ready and able to use highly effective methods of&#xD;
             birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per&#xD;
             year when used consistently and correctly. A list of contraception methods meeting&#xD;
             these criteria is provided in the patient information&#xD;
&#xD;
          -  Signed informed consent consistent with ICH GCP guidelines and local legislation prior&#xD;
             to participation in the trial, which includes medication washout and restrictions&#xD;
&#xD;
          -  Not under any administrative or legal supervision or under institutionalization due to&#xD;
             regulatory or juridical order&#xD;
&#xD;
          -  Further inclusion criteria apply&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Additional eye disease in the study eye that could compromise best corrected Visual&#xD;
             Acuity (VA)(BCVA) with visual field loss, uncontrolled glaucoma (Intra-Ocular Pressure&#xD;
             (IOP)&gt;24), clinically significant diabetic maculopathy, history of ischemic optic&#xD;
             neuropathy or retinal vascular occlusion, symptomatic vitreomacular traction, or&#xD;
             genetic disorders such as retinitis pigmentosa); history of high myopia &gt; 8 diopters&#xD;
             in the study eye. Anterior segment and vitreous abnormalities in the study eye that&#xD;
             would preclude adequate observation with Spectral Domain Optical Coherence Tomography&#xD;
             (SD-OCT)&#xD;
&#xD;
          -  Any prior intraocular surgery in the study eye other then uneventful lens replacement&#xD;
             for cataract within 3 months prior to screening&#xD;
&#xD;
          -  Aphakia or total absence of the posterior capsule. Yttrium aluminum garnet (YAG) laser&#xD;
             capsulotomy permitted, more than 3 month prior to enrollment in the study eye&#xD;
&#xD;
          -  Current or planned use of medications known to be toxic to the retina, lens or optic&#xD;
             nerve (e.g. desferoxamine, chloroquine/hydrochloroquine, chlorpromazine,&#xD;
             phenothiazines, tamoxifen, nicotinic acid, and ethambutol)&#xD;
&#xD;
          -  Medical history or condition: Uncontrolled diabetes mellitus, with hemoglobin A1c&#xD;
             (HbA1c) &gt; 10%, myocardial infarction or stroke within 12 months of screening, active&#xD;
             bleeding disorder, concomitant use of warfarin or anticoagulation therapy (use of&#xD;
             antiplatelet therapy such as aspirin is allowed), major surgery within 1 month of&#xD;
             screening or when planned within the study period, hepatic impairment, uncontrolled&#xD;
             hypertension&#xD;
&#xD;
          -  Patients with a clinically relevant abnormal screening haematology, blood chemistry,&#xD;
             or urinalysis, if the abnormality defines a significant disease as defined in other&#xD;
             exclusion criteria. AST or ALT greater than 2.0-fold the upper limit of normal at&#xD;
             screening. Patients with total bilirubin 2.5x upper limit of normal at screening.&#xD;
&#xD;
          -  Patient with impaired renal function defined as calculated GFR&lt; 30 mL/min&#xD;
&#xD;
          -  Significant alcohol or drug abuse within past 2 years per investigator judgement&#xD;
&#xD;
          -  Participation in trials:&#xD;
&#xD;
               -  Previous participation in this trial.&#xD;
&#xD;
               -  Previous participation in other trials for treatment of wAMD with systemic&#xD;
                  administration and/orif washout period from last administration is shorter than 3&#xD;
                  months.&#xD;
&#xD;
               -  MRD cohort 1: Previous participation in other trials for treatment of wAMD with&#xD;
                  IVT injections in the study eye if washout period from last&#xD;
                  administration/injection is shorter than 3 months.&#xD;
&#xD;
               -  MRD cohort 2: No previous IVT injections for wAMD in the study eye&#xD;
&#xD;
          -  Significant disease or other medical conditions (as determined by medical history,&#xD;
             examination and clinical investigations at screening) that may, in the opinion of the&#xD;
             investigator result in the any of the following:&#xD;
&#xD;
               -  Put the patient at risk because of participation in the study,&#xD;
&#xD;
               -  Influence the results of the study,&#xD;
&#xD;
               -  Cause concern regarding the patient's ability to participate in the study.&#xD;
&#xD;
          -  Known hypersensitivity to fluorescein or any of the ingredients used in the&#xD;
             Investigational Medicinal Product (IMP) formulation, or any of the medications used&#xD;
&#xD;
          -  Active intraocular inflammation in the study eye&#xD;
&#xD;
          -  Active infectious conjunctivitis in either eye&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Retina Institute of California Medical Group</name>
      <address>
        <city>Palm Desert</city>
        <state>California</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Samuel</last_name>
      <phone>+001(760)269-4499</phone>
      <email>msamuel@acuityeyegroup.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Quan Nguyen</last_name>
      <phone>+001(650)724-4280</phone>
      <email>ndquan@stanford.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cumberland Valley Retina Consultants, PC.</name>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allen Hu</last_name>
      <phone>+001(301)665-1712-x205</phone>
      <email>allenh@retinacare.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New York Eye and Ear Infirmary of Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Rosen</last_name>
      <phone>+001(212)979-4288</phone>
      <email>rrosen@nyee.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Verum Research, LLC</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert Edwards</last_name>
      <phone>+001(541)762-2763</phone>
      <email>aoedwards@verumresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Brucker</last_name>
      <phone>+001(215)662-9702</phone>
      <email>ajbrucke@mail.med.upenn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Retina Research Institute of Texas</name>
      <address>
        <city>Abilene</city>
        <state>Texas</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sunil Patel</last_name>
      <phone>+001(325)690-4414</phone>
      <email>dr.patel@txicr.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Retina Research Center, PLLC</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Berger</last_name>
      <phone>+001(512)279-1251</phone>
      <email>bberger@retinaresearchcenter.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Texas</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Brown</last_name>
      <phone>+001(713)524-3434</phone>
      <email>dmbmd@retinaconsultantstexas.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oliver Zeitz</last_name>
      <phone>+49(30)84452334</phone>
      <email>oliver.zeitz@charite.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Göttingen, Georg-August-U</name>
      <address>
        <city>Göttingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Feltgen</last_name>
      <phone>+49(551)3964801</phone>
      <email>nicolas.feltgen@med.uni-goettingen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armin Wolf</last_name>
      <phone>+4973150059001</phone>
      <email>Armin.Wolf@uniklinik-ulm.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bristol Eye Hospital</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Serena Salvatore</last_name>
      <phone>+441179230060</phone>
      <email>Serena.Salvatore@UHBristol.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool University Hospital</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Savita Madhusudhan</last_name>
      <phone>+441517062000</phone>
      <email>Savita.Madhusudhan@rlbuht.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Moorfields Eye Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sobha Sivaprasad</last_name>
      <phone>02075662117</phone>
      <email>Sobha.sivaprasad@nhs.net</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mystudywindow.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 26, 2019</study_first_submitted>
  <study_first_submitted_qc>March 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2019</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:&#xD;
studies in products where Boehringer Ingelheim is not the license holder;&#xD;
studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials;&#xD;
studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).&#xD;
For more details refer to: https://www.mystudywindow.com/msw/datasharing</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

